Dividends & Buybacks ·
Fractyl Health, Inc. received notification from Nasdaq on September 10, 2026, that its common stock is subject to…
GUTSFractyl Health, Inc.
Fractyl Health, Inc. received notification from Nasdaq on September 10, 2026, that its common stock is subject to delisting because the minimum bid price remained below $1.00 for 30 consecutive business days and failed to regain compliance within the 180-day grace period. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the outcome. To address the deficiency, Fractyl filed a proxy statement on August 24, 2026, seeking shareholder approval for a reverse stock split with a ratio ranging from 1-for-5 to 1-for-15. The company operates in the healthcare sector, specifically developing therapies for metabolic diseases.